Heat Biologics, Inc. (HTBX): Price and Financial Metrics

Heat Biologics, Inc. (HTBX)

Today's Latest Price: $6.34 USD

0.13 (2.09%)

Updated Jan 15 4:00pm

Add HTBX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

HTBX Stock Summary

  • With a year-over-year growth in debt of 453.86%, Heat Biologics Inc's debt growth rate surpasses 96.15% of about US stocks.
  • In terms of volatility of its share price, HTBX is more volatile than 98.6% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HTBX comes in at -84.91% -- higher than that of merely 3.28% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heat Biologics Inc are PI, IMAB, NVTA, ARLO, and QLYS.
  • HTBX's SEC filings can be seen here. And to visit Heat Biologics Inc's official web site, go to www.heatbio.com.

HTBX Stock Price Chart Interactive Chart >

Price chart for HTBX

HTBX Price/Volume Stats

Current price $6.34 52-week high $30.10
Prev. close $6.21 52-week low $1.37
Day low $6.14 Volume 2,067,300
Day high $6.85 Avg. volume 965,570
50-day MA $6.65 Dividend yield N/A
200-day MA $7.75 Market Cap 144.55M

Heat Biologics, Inc. (HTBX) Company Bio

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

HTBX Latest News Stream

Event/Time News Detail
Loading, please wait...

HTBX Latest Social Stream

Loading social stream, please wait...

View Full HTBX Social Stream

Latest HTBX News From Around the Web

Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Stocks News Feed

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. (“Heat”) (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually… Read More »Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Stocks News Feed | January 8, 2021

Why Covid-19 Product Market Trending in 2021? Know COVID-19 Impact on Growth and Forecast Research till 2027 | 3M, Cardinal Health, Kimberly- Clark, Johnson and Johnson, Sanofi, Ansell, Abbott, BD, Henry Schein, Heat Biologics

A report by The Insight Partner's on the Global Covid-19 Product Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in

OpenPR | January 7, 2021

Covid-19 Product Market With Top Players like 3M, Cardinal Health, Kimberly- Clark, Johnson and Johnson, Sanofi, Ansell, Abbott Laboratories, BD, Henry Schein, Heat Biologics

Covid-19 Product include range of products which are used for protection against covid-19. The range of products mainly include, face mask, sanitizers, disinfectant, personal protection equipment, hand gloves, oximeters and such other products. The covid-19 outbreak has drastically enhanced the

OpenPR | December 10, 2020

Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | December 10, 2020

Heat Biologics Provides Business Update

DURHAM, NC / ACCESSWIRE / December 10, 2020 / Heat Biologics, Inc.

Yahoo | December 10, 2020

Read More 'HTBX' Stories Here

HTBX Price Returns

1-mo 10.45%
3-mo -23.89%
6-mo -69.50%
1-year 174.54%
3-year -73.36%
5-year -95.77%
YTD 18.28%
2020 61.20%
2019 -51.53%
2018 -74.41%
2017 -55.47%
2016 -64.75%

Continue Researching HTBX

Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:

Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7543 seconds.